Evista (raloxifene) is now approved to TREAT osteoporosis

November 1999

Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for prevention.

Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.

This is comparable to the decrease in vertebral fractures that's seen with Fosamax (alendronate)...even though Evista doesn't increase bone density as much as Fosamax.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote